Search bioRxivSearch

bioRxiv · 10.1101/2020.01.14.906826

Dynamic metabolic reprogramming in dendritic cells: an early response to influenza infection that is essential for effector function

Abstract

Infection with the influenza virus triggers an innate immune response aimed at initiating the adaptive response to halt viral replication and spread. However, the metabolic response fueling the molecular mechanisms underlying changes in innate immune cell homeostasis remain undefined. Thus, we compared the metabolic response of dendritic cells to that of those infected with active and inactive influenza A virus or treated with toll like receptor agonists. While influenza infects dendritic cells, it does not productively replicate in these cells, and therefore metabolic changes upon infection may represent an adaptive response on the part of the host cells. Using quantitative mass spectrometry along with pulse chase substrate utilization assays and metabolic flux measurements, we found global metabolic changes 17 hours post infection, including significant changes in carbon commitment via glycolysis and glutaminolysis, as well as ATP production via TCA cycle and oxidative phosphorylation. Influenza infection of dendritic cells led to a metabolic phenotype, distinct from that induced by TLR agonists, with significant resilience in terms of metabolic plasticity. We identified Myc as one transcription factor modulating this response. Restriction of either Myc activity or mitochondrial substrates resulted in significant changes in the innate immune functions of dendritic cells, including reduced motility and T cell activation. Transcriptome analysis of inflammatory dendritic cells isolated following influenza infection showed similar metabolic reprogramming occurs in vivo. Thus, early in the infection process dendritic cells respond with global metabolic restructuring that is present in lung DC 9 days following infection and impacts their effector function, suggesting that metabolic switching in dendritic cells plays a vital role in initiating the immune response to influenza infection. Author SummaryIn response to influenza infection we found that dendritic cells, cells that are critical in mounting an effective immune response, undergo a profound metabolic shift. They alter the concentration and location of hundreds of proteins, including c-MYC, mediating a shift to a highly glycolytic phenotype that is also flexible in terms of fueling respiration. Dendritic cells initiate the immune response to influenza and activate the adaptive response allowing viral clearance and manifesting immune memory for protection against subsequent infections. We found that limiting access to specific metabolic pathways or substrates diminished key immune functions. Previously we described an immediate, fixed, hypermetabolic state in infected respiratory epithelial cells. We now show the metabolic responses of epithelial and dendritic cells are distinct. Here, we also demonstrate that dendritic cells tailor their metabolic response to the pathogen or TLR stimulus. This metabolic reprogramming occurs rapidly in vitro and it is sustained in inflammatory dendritic cells in vivo for at least 9 days following influenza infection. Thus, drugs targeting metabolism are likely to have cell- and pathogen-specific activities in the context of infection. These studies open the possibility of modulating the immune response to viral infection via customizing metabolic therapy to enhance or diminish the function of specific cells.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Smallwood, H., Rezinciuc, S., Bezavada, L., Bahadoran, A., Dan, S., Wang, R., Ferrer, D. L., Zink, E. E., Finklestein, D., Green, D. R., Tolic, L. P., Thomas, P. G.. 2020-01-14. Dynamic metabolic reprogramming in dendritic cells: an early response to influenza infection that is essential for effector function. https://doi.org/10.1101/2020.01.14.906826

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

De novo design of CR2 binder as vaccine scaffold

Efficient B cell activation during vaccine-induced humoral immunity relies on both B cell receptor (BCR) antigen recognition and synergistic signaling from co-receptors. Complement receptor 2 (CR2), the primary BCR co-receptor on B cells, lowers the activation threshold and amplifies downstream kinase signaling by orders of magnitude when engaged by complement fragment C3d decorated antigens. Targeting CR2 therefore represents a rational vaccine enhancement strategy, yet native C3d suffers from low affinity, poor stability, and manufacturing challenges. Here, we report the de novo design of a highly stable, high-affinity CR2 binder using deep learning driving protein design methods. Biophysical characterization, high-resolution cryoEM structural determination, and functional assays in vitro and in vivo confirm that the designed binder matches computational design models and specifically engages CR2 to boost B cell activation. When fused to antigen as a vaccine scaffold, the trimeric CR2 binder elicits robust humoral immune responses comparable to nanoparticle vaccines, while retaining the simplicity of single-chain protein production. Our work establishes a modular CR2 targeting vaccine scaffold platform with broad translational potential for next-generation protein vaccines.

immunology

Chronic opioid-associated immune dysregulation among people living with HIV

Objectives: Persistent immune dysregulation contributes to chronic disease among people living with HIV (PWH), even after viral suppression with antiretroviral therapy (ART). Although chronic opioid exposure is associated with adverse clinical outcomes, its impact on immune homeostasis during ART remains incompletely understood. We investigated whether opioid use disorder (OUD) is associated with persistent systemic and cellular immune dysregulation despite ART-mediated reductions in HIV viral load (VL). Methods: Peripheral blood was collected longitudinally from PWH with OUD (PWH/OUD+) and detectable HIV VL during 6 months of optimized ART (months 0, 3, and 6). A reference cohort of PWH without OUD (PWH/OUD-) and suppressed HIV VL provided a single blood sample. Immune profiling included plasma inflammatory biomarkers, multiplex cytokine analyses, spectral flow cytometry, and assessment of monocyte cytokine responses following lipopolysaccharide (LPS) stimulation. Mixed-effects models adjusted for HIV VL and VL-stratified analyses were performed. Results: PWH/OUD+ exhibited persistent immune dysregulation despite reductions in HIV VL. Plasma sCD163, sCD14, fractalkine, and I-TAC remained elevated, whereas TGF-{beta}1 was reduced. OUD was associated with expansion of CD16 monocytes and altered expression of CCR2, CD38, and CD11b. CD4 and CD8 T cells, NK cells, and B cells also exhibited persistent alterations in markers of activation, metabolism, and trafficking. Monocytes from PWH/OUD+ displayed attenuated cytokine responses following LPS stimulation. Conclusions: OUD is associated with persistent systemic and cellular immune dysfunction in PWH despite ART-mediated viral suppression, supporting opioid exposure as an independent contributor to chronic immune dysregulation that may promote inflammation, immune dysfunction, and long-term HIV-associated comorbidities. Keywords: HIV, Opioid-use disorder, innate immunity, cytokine

immunology

The mitochondrial RNA extrusion-induced innate immunity is regulated by N6-methyladenosine machinery

Mitochondrial RNA (mtRNA) released into the cytosol functions as a damage associated molecular pattern that activates pattern-recognition receptor (PRR)-mediated inflammation, yet its release mechanisms and cytoplasmic fate remain poorly understood. Here we report that chemical Abt-373-treatment and Vesicular stomatitis virus (VSV) infection induce mtRNA extrusion through Bax/Bak and VDAC1 channels, accompanied by mtDNA release. Extruded mtRNA in A549 cells activates multiple cytosolic PRRs, including RIG-I, MDA5, TLR3/7/8, and PKR, each contributing differentially to the innate immune signaling. Analysis of GEO datasets and methylated RNA immunoprecipitation (MeRIP) assays further reveals that mtRNA carries methyladenosine (m6A) modification. m6A machinery proteins are involved in the cytoplasmic retention time of mtRNA and its interaction with RIG-I, thereby modulating mtRNA-induced innate immunity. Thus, our work establishes in vitro models of mtRNA extrusion, and highlights m6A-dependent modulation as a potential therapeutic target for mtRNA-driven inflammation.

immunology